Latest Peplin news

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

Letter to our CDI Holders read more

Archived 2005

15-12-2005	Capital raising to advance actinic keratosis trials program	35 kb
08-12-2005	Skin cancer trial completes enrolment / PEP005 IV for leukemia update	34 kb
28-11-2005	Peplin announces positive phase IIa trial results	71 kb
17-11-2005	Anti-cancer data presented at international cancer conference	81 Kb
28-10-2005	Update - reporting of clinical trial results	40 Kb
18-10-2005	Results of Annual General Meeting held on 14 October 2005	47 Kb
13-10-2005	Positive anti-leukemia effects of PEP005 IV	45 Kb
12-10-2005	Construction of new commercial scale manufacturing facility	39 Kb
06-10-2005	Peplin to present at Wilson HTM investor conference	34 Kb
08-09-2005	Michael Aldridge to present at healthcare conference	34 Kb
01-09-2005	Start of US dose escalation clinical trial	44 Kb
30-08-2005	Wayne Goss to retire as Peplin director	3 Kb
09-08-2005	Results for the financial year ended 30 June 2005	3 Kb
02-08-2005	Capital raising to advance leukemia program	39 Kb
12-07-2005	UK news story - Peplin's PEP005 anti-leukemia drug	34 Kb
30-06-2005	Price query from ASX and response	132 Kb
30-06-2005	Peplin progress PEP005 Topical treatment	42 Kb
26-04-2005	PEP005's potent anti-leukemia results published	34 Kb
06-04-2005	Peplin granted US patent	33 Kb
31-03-2005	Peplin offered $5.6 million Government grant	35 Kb
17-03-2005	Peplin starts phase II clinical trials	58 Kb
08-02-2005	Peplin First Half Results	50 Kb
19-01-2005	Contract clinical development collaboration	39 Kb
10-01-2005	Exciting results from phase 1 clinical trial	16 Kb